Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

142

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions

Traveler's Diarrhea

Interventions

DRUG

Rifamycin SV MMX

200 mg Rifamycin SV-MMX® (CB-01-11)

DRUG

Placebo to Rifamycin SV-MMX

Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.

All Listed Sponsors

lead

RedHill Biopharma Limited

INDUSTRY